Form 4: Cellectar Biosciences Director Douglas J. Swirsky Acquires 90,000 Stock Options

Director Douglas J. Swirsky acquired 90,000 stock options in Cellectar Biosciences following stockholder approval of the amended 2021 Stock Incentive Plan.

Summary

• Douglas J. Swirsky, a director of Cellectar Biosciences, acquired 90,000 stock options on June 14, 2024.
• The options were granted contingently on December 22, 2023, pending stockholder approval of Cellectar's amended 2021 Stock Incentive Plan.
• Stockholder approval was obtained on June 14, 2024, at Cellectar's 2024 Annual Meeting of Stockholders.
• The exercise price of the options is $2.58.
• The options vest in full on December 22, 2024, subject to Swirsky's continued service.
• The options expire on December 22, 2033.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a routine transaction (stock option grant) that aligns management interests with shareholders. The director's acquisition of options suggests confidence in the company's future.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with those of shareholders, potentially encouraging value creation.
• Employees: The grant is part of the company's overall compensation strategy.

Key Dates

Keywords

stock options, Cellectar Biosciences, director, Douglas J. Swirsky, stockholder approval, 2021 Stock Incentive Plan, CLRB